Pizotyline (BC 105)

01/23/2008 - "Symon et al report a cross-over trial comparing pizotifen and placebo in 16 children with "abdominal migraine". "
01/01/2002 - "This cross-over trial in 14 children who met suggested criteria for "abdominal migraine" compared pizotifen and placebo, each given for one month with no washout period. "
08/01/1995 - "Double blind placebo controlled trial of pizotifen syrup in the treatment of abdominal migraine."
01/01/1995 - "Fourteen children with abdominal migraine were treated with pizotifen and placebo in a double blind crossover trial. "
01/01/1995 - "Double blind placebo controlled trial of pizotifen syrup in the treatment of abdominal migraine."

01/01/1985 - "Pretreatment with pizotifen (a serotonergic receptor antagonist) had no significant effect on tremor. "
01/01/1972 - "Parkinson's tremor, relief by an antiaminic drug (BC 105). "
09/01/1980 - "Treatment with propranolol and pizotyline lessened the number of episodes of hemiplegia and improved the tremor. "
05/01/1978 - "[Pizotifen (Sandomigran) used in the treatment of parkinsonian tremor (preliminary communication)]."
05/01/1978 - "On the basis of the concepts connecting parkinsonian tremor with reduced amount of serotonin in the striatum and in the light of the hypothesis of an agonistic action of pizotifen in relation to serotonin a trial was undertaken to reduce parkinsonian tremor in 12 patients administering Sandomigran in daily doses of 1.5 mg. A significant reduction of tremor was achieved in two-thirds of these patients. "

07/01/1974 - "[Sandomigran in the prevention of headaches following lumbar puncture]."
07/01/1970 - "[Therapeutic action of an antiamine drug (BC 105) in vasomotor headaches]."
05/05/1970 - "[Clinical experiences with polyantiaminic BC-105 Sandoz in the prevention of vasomotor headaches]."
01/01/1982 - "Pizotifen in the treatment of severe recurrent headache single and divided dose therapy compared."
01/01/1971 - "[Therapy of vasomotor headache with a new drug: BC 105. "

01/01/2022 - "Pizotifen, a 5-HT2 receptor antagonist, is currently used in the prevention of vascular headaches. "
11/01/1969 - "[Tests of BC 105 in 20 cases of vascular headache]."
01/01/1974 - "A cooperative study on the clinical aspects of migraine and vascular headache and their response to sandomigran."
10/01/1977 - "These properties, and the well-documented effect of pizotifen in migraine, could make it an alternative in treating patients suffering from the often seen combination of vascular headache/depression."
01/01/1972 - "Pizotifen (BC-105): a review of its pharmacological properties and its therapeutic efficacy in vascular headaches."

01/01/2022 - "Here we find that intrathecal pizotifen attenuates neuropathic and inflammatory pain mainly due to elevated GABAergic synaptic inhibition. "
01/01/2022 - "Intrathecally administered pizotifen alleviates neuropathic and inflammatory pain in mice by enhancing GABAergic inhibition."
03/01/1985 - "Flunarizine tended to more markedly suppress severity of pain and duration of attacks than pizotifen. "
01/01/2022 - "In summary, our findings suggest that pizotifen strengthens the inhibitory synaptic transmission and exerts antinociceptive effect on both neuropathic pain and inflammatory pain in the spinal cord, and may serve as a promising remedy for chronic pain."
01/01/2022 - "However, the antinociceptive effect of pizotifen on non-headache pain especially chronic pain in the spinal level is still unknown. "